Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06701812 · ClinicalTrials.gov registry record · Phase 2
Digoxin Medulloblastoma Study
A Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 15
- Study locations
NCT06701812: Recruiting Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06701812 is a Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 23 participants, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (84% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06701812, a Phase 2 study of Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Primary Outcome
Proportion of patients with progression free survival at 4 months after initiation of treatment.
Conditions Studied
Interventions
- DRUG Digoxin
Study Locations (15)
Florida
- Nemours Jacksonville - Jacksonville
- University of Miami - Miami
- Johns Hopkins All Children's - St. Petersburg
- St. Joseph's Children's Hospital - Tampa
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
- Levine Cancer Institute - Charlotte
Alabama
- University of Alabama at Birmingham Children's of Alabama - Birmingham
Arkansas
- Arkansas Childrens Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Missouri
- Washington University St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT06701812 shows while recruiting
NCT06701812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 140-participant average among 29 other Medulloblastoma trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Medulloblastoma appearing as the primary indexed condition, and to 1 intervention - of which Digoxin is the first listed.
NCT06701812 lists 15 locations in 11 states (Florida, North Carolina, Alabama).
Frequently Asked Questions
What is clinical trial NCT06701812 about?
NCT06701812 is a clinical study titled "Digoxin Medulloblastoma Study". The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
What is the current status of trial NCT06701812?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2026-01-15. Estimated completion is 2027-02.
What conditions does trial NCT06701812 study?
This clinical trial studies the following conditions: Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH.
What interventions are being tested in trial NCT06701812?
The interventions under investigation include: Digoxin (DRUG).
Who is sponsoring clinical trial NCT06701812?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06701812 being conducted?
This trial has 15 study locations across Alabama, Arkansas, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06701812's enrollment target sits among peer trials
23 22nd of 29 higher than 8 of 29 other Medulloblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Medulloblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
-
Methionine PET/CT Studies In Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI